MedWatch

Deborah Dunsire is breaking an old pattern: The definition of madness is doing the same thing over and over, expecting a different outcome

In her first three years at Lundbeck, one of Deborah Dunsire's missions has been to rethink the pipeline and the way in which clinical trials are carried out, attempting to avoid more big and costly failures in clinical development at the company.

Photo: Lars Krabbe/Foto: Lars Krabbe/Ritzau Scanpix

Few and far between have been product launches at Lundbeck the past few years, including the three years led by Deborah Dunsire, with the only new launch being that of Vyepti, which is – for Lundbeck – a relatively new area: migraine.

Lundbeck, under the leadership of Dunsire, has chosen this approach in particular because of the problems with the lack of launches. The company has suffered several failures with substances in late stages, of which idalopirdine and Lu AF35700 have been the most noteworthy. This is a statistic that Dunsire is set on changing.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Coloplast upgrades growth expectations following acquisition

Medtech firm Coloplast’s Q1 report for 2021/2022 brings a slight upward adjustment of the reported revenue growth outlook due to foreign exchange developments. Coloplast’s acquisition of Atos Medical is expected to contribute around 6 percent to organic growth.

Demant's surgical division loses president of 13 years

Oticon Medical, the implants division at hearing group Demant, is saying goodbye to President Jes Olsen, who is exiting his role in March after having spearheaded the business leg since 2008. Demant CEO Søren Nielsen is stepping in temporarily until a replacement is found.

Hearing aid market in US grew by 37 percent in 2021

Hearing aid manufacturers have had a good year following one of the worst in their recorded history, as sales in the US have gone up by 37 percent. The progress is mainly driven by the recovery of independent retailers, whereas public sales channel Veterans Affairs still lags behind.

Further reading

Related articles

Latest news

See all jobs